Ravesanker Ezhilarasan
Overview
Explore the profile of Ravesanker Ezhilarasan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim S, Joshi K, Ezhilarasan R, Myers T, Siu J, Gu C, et al.
Stem Cell Reports
. 2024 Oct;
19(10):1516.
PMID: 39389676
No abstract available.
2.
Karp J, Modrek A, Ezhilarasan R, Zhang Z, Ding Y, Graciani M, et al.
JCI Insight
. 2024 Aug;
9(19).
PMID: 39190500
Tumor-educated platelets (TEPs) are a potential method of liquid biopsy for the diagnosis and monitoring of cancer. However, the mechanism underlying tumor education of platelets is not known, and transcripts...
3.
Stitzlein L, Gangadharan A, Walsh L, Nam D, Espejo A, Singh M, et al.
Front Neurol
. 2023 Apr;
14:1112207.
PMID: 37082446
Introduction: Improved therapies for glioblastoma (GBM) are desperately needed and require preclinical evaluation in models that capture tumor heterogeneity and intrinsic resistance seen in patients. Epigenetic alterations have been well...
4.
Zhang Z, Ding Y, Ezhilarasan R, Lhakhang T, Wang Q, Yang J, et al.
Cell Discov
. 2022 Oct;
8(1):102.
PMID: 36202798
Targeted cancer therapies have revolutionized treatment but their efficacies are limited by the development of resistance driven by clonal evolution within tumors. We developed "CAPTURE", a single-cell barcoding approach to...
5.
Modrek A, Eskilsson E, Ezhilarasan R, Wang Q, Goodman L, Ding Y, et al.
Front Oncol
. 2022 Sep;
12:941657.
PMID: 36059614
Treatment-resistant glioma stem cells are thought to propagate and drive growth of malignant gliomas, but their markers and our ability to target them specifically are not well understood. We demonstrate...
6.
Yang J, Wang Q, Zhang Z, Long L, Ezhilarasan R, Karp J, et al.
Nat Commun
. 2022 Jul;
13(1):4410.
PMID: 35906213
Molecular classification has improved diagnosis and treatment for patients with malignant gliomas. However, classification has relied on individual assays that are both costly and slow, leading to frequent delays in...
7.
Chen Z, Herting C, Ross J, Gabanic B, Vallcorba M, Szulzewsky F, et al.
Glia
. 2020 Jul;
68(10):2148-2166.
PMID: 32639068
Glioblastoma (GBM) is the most aggressive primary brain tumor. In addition to being genetically heterogeneous, GBMs are also immunologically heterogeneous. However, whether the differences in immune microenvironment are driven by...
8.
Pradhan D, Jour G, Milton D, Vasudevaraja V, Tetzlaff M, Nagarajan P, et al.
Cancers (Basel)
. 2020 Jan;
11(12).
PMID: 31888295
Acral melanoma (AM) is a rare, aggressive type of cutaneous melanoma (CM) with a distinct genetic profile. We aimed to identify a methylome signature distinguishing primary acral lentiginous melanoma (PALM)...
9.
Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma E, Ezhilarasan R, et al.
Clin Cancer Res
. 2019 Dec;
26(6):1395-1407.
PMID: 31852834
Purpose: Exploration of novel strategies to extend the benefit of PARP inhibitors beyond -mutant cancers is of great interest in personalized medicine. Here, we identified amplification as a potential biomarker...
10.
Farooqi A, Yang J, Sharin V, Ezhilarasan R, Danussi C, Alvarez C, et al.
Acta Neuropathol Commun
. 2019 May;
7(1):76.
PMID: 31097032
No abstract available.